Corubrutinib vs remibrutinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: Bruton's tyrosine kinase (BTK) · full Multiple Sclerosis pipeline
Corubrutinib
Developed by Biogen
NCT05798520 · Phase 2 · completed
The study randomized 127 participants and used quadruple blinding with active and matching-placebo comparator arms. Its primary outcomes included adverse events and new MRI lesions.
Company statement of 2026-07-29 (Q2 results); no efficacy figures published yet.
Reported efficacy
Part 1: Number of Participants With Adverse Events (AEs) (Day 1 up to Week 50); Part 1: Number of Participants With Serious Adverse Events (SAEs) (From signing the informed consent form (ICF) to Week 50); Part 2: Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions (Week 8 to Week 16): Biogen reported that BIIB091 achieved proof-of-concept in relapsing-remitting MS (no figures released)
Result source: NCT05798520
remibrutinib
Marketed by Novartis
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: July 2029 · NCT06846281 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Multiple Sclerosis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Corubrutinib | remibrutinib |
|---|---|---|
| Annualised relapse rate | —Not reported | —Trial running · NCT07225504 |
| Free of 3-month confirmed disability progression (%) | —Not reported | —Trial running · NCT07225504 |
| New or enlarging T2 lesions | —Not reported | —Trial running · NCT07225504 |
Annualised relapse rate
- Corubrutinib
- —Not reported
- remibrutinib
- —Trial running · NCT07225504
Free of 3-month confirmed disability progression (%)
- Corubrutinib
- —Not reported
- remibrutinib
- —Trial running · NCT07225504
New or enlarging T2 lesions
- Corubrutinib
- —Not reported
- remibrutinib
- —Trial running · NCT07225504
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
remibrutinib: no structured comparison results are available for Multiple Sclerosis.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Corubrutinib's landscape · remibrutinib's landscape